Results for tag: "Hereditary Spastic Paraplegias Drug"

Hereditary Spastic Paraplegias (HSP) is a group of rare neurological disorders characterized by progressive lower limb spasticity and weakness. It is caused by mutations in genes that are involved in the maintenance of the axon, the long projection of a neuron that carries electrical signals away from the cell body. Treatment of HSP is mainly symptomatic and includes physical therapy, orthopedic surgery, and medications. The Hereditary Spastic Paraplegias Drug market is a subset of the Central Nervous System Drugs market. It is a small but growing market, driven by the increasing prevalence of HSP and the development of new treatments. Currently, there are no approved drugs specifically for HSP, but several drugs are being investigated in clinical trials. Some companies in the Hereditary Spastic Paraplegias Drug market include Biogen, Novartis, and Sanofi. Other companies such as AbbVie, AstraZeneca, and Pfizer are also researching potential treatments for HSP. Show Less Read more